GSK

News

ViiV's Cabenuva enhances control of unsuppressed HIV

ViiV's long-acting injectable HIV drug, Cabenuva, has proved to be more effective than daily oral therapy for unsuppressed infections.

News

GSK wagers $750m on Chimagen multiple myeloma therapy

GSK has continued a drive to bulk up its pipeline, taking global rights to a T-cell engager for multiple myeloma, developed by China's Chimagen Bio.

News

GSK showcases positive data with lung cancer drugs at WCLC

New data at WCLC26 could push GSK's ROS1+ NSCLC drug Jideytro into the first-line setting, while B7-H3-targeted ADC ris-rez extends survival in SCLC.

News

Hutchmed rises on $1.3bn KRAS licensing deal with GSK

GSK has paid Hutchmed $110m upfront for rights to a preclinical KRAS and EGFR-directed drug with potential in colorectal, pancreatic, and lung cancer.

News

GSK pushes 'next-generation' mRNA flu shot into phase 3

Buoyed by positive data in a phase 2 trial, GSK will start a phase 3 programme for an mRNA-based flu shot targeting both HA and NA flu antigens.

News

Trodelvy gets EU nod for first-line triple-neg breast cancer

A new EC authorisation expands Gilead's market for triple-negative breast cancer ADC Trodelvy.

ViiV's Cabenuva enhances control of unsuppressed HIV

GSK wagers $750m on Chimagen multiple myeloma therapy

GSK showcases positive data with lung cancer drugs at WCLC

Hutchmed rises on $1.3bn KRAS licensing deal with GSK

GSK pushes 'next-generation' mRNA flu shot into phase 3

Trodelvy gets EU nod for first-line triple-neg breast cancer

Brent Saunders ejects from Bausch + Lomb once again

Discover a new era of healthcare panel engagement: Grounded ...

GSK

Editor's Picks